The final decision includes some changes, most notably removing requirements for guideline inclusion, but retains its technical performance benchmarks.
The company has reached agreements with investors for a direct offering of 2.2 million shares at $1 per share, for gross proceeds of about $2.2 million.
The firm sells a rapid, point-of-care, PCR platform for infectious disease diagnostics, including SARS-CoV-2, influenza, respiratory syncytial virus, and strep A.
The company, which is developing instrument-free, low-cost molecular diagnostics platform for infectious disease testing, plans to float its shares on the Nasdaq.
The company's DETECTR disease detection platform will be used to help develop the technology and optimize the CRISPR enzymes used in the point-of-care device.